Abstract:
Objective This study aims to discuss the effect of Jinlong capsule on decreasing adverse reaction after transcatheter arterial chemoembolization(TACE)for patients with heptocellular carcinoma.
Methods We divided 82 patients with heptocellular carcinoma into the contrast group and experiment group using random principle.On the first day after TACE, the experiment group started to take Jinlong capsule orally, whereas the contrast group did not; other treatment methods were the same.
Results The decreased cases of the red blood cell and thrombocyte in the experiment group were lower than those in the contrast group(P < 0.05);the variance of the total bilirubin had no statistical significance between the two groups(P > 0.05), whereas statistical significance was observed on the variance of Alanine transaminase, albumin, potassium, and sodium in the blood between two groups(P < 0.05).Five days after TACE, the score of appetite, energy, sleep, and fatigue for the experiment group were superior to the contrast group; the persistence of stomachache and abdominal distension in the experiment group were shorter than that in the contrast group(P < 0.05).
Conclusion Jinlong capsule can decrease the incidence of partial adverse reaction after TACE, cut short the persisting time of adverse reaction, improves the quality of life after TACE, and reduces damage to organs caused by TACE.